OUP user menu

Journal of Crohn's and Colitis: 9 (9)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

6.234
5.425

Published on behalf of

EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after adalimumab treatment

Li Liu, Aline Charabaty, Metin Ozdemirli
DOI: http://dx.doi.org/10.1016/j.crohns.2012.07.025 e118-e119 First published online: 1 April 2013

Dear Sir,

Adalimumab is a third tumor necrosis factor (TNF) inhibitor approved in the US for the treatment of Crohn's disease. However, sporadic cases of lympho-proliferative disorders have been reported in association with adalimumab therapy.1,2 In order to fully assess the long-term safety associated with adalimumab and anti-TNF in general, it is necessary to report any drug-associated malignancy, especially when these occur in unusual locations; a prompt diagnosis is crucial to start treatment and increase the chance of patient survival. Herein we report a rare case of EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after treatment …

Log in through your institution